FindTrial
Sign In

HDAC inhibitor AR-42

DRUG2 trials

Sponsors

Alison Walker, Ohio State University Comprehensive Cancer Center

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid Leukemia

Phase 1

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
CompletedNCT01798901
Alison WalkerAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +7
Start: 2013-09-17End: 2015-02-19Updated: 2018-03-14
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
CompletedNCT02569320
Ohio State University Comprehensive Cancer CenterRecurrent Plasma Cell Myeloma
Start: 2016-05-20End: 2021-03-10Updated: 2021-06-15

Related Papers

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
2021-10-073 citations